Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/2 open-label trial.
Overview
- Department of Neurology, Skåne University Hospital, Lund, Sweden
- Department of Clinical Sciences and Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
- Department of Neurosurgery, Skåne University Hospital, Lund, Sweden
- Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Experimental Medical Science, Wallenberg Neuroscience Center and Lund Stem Cell Center, Lund University, Lund, Sweden
- Clinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
- Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK
- Department of Brain Sciences, Imperial College London, London, UK
- Clinical Studies Sweden - Forum South, Skåne University Hospital, Lund, Sweden
- Lund Stem Cell Center and Division of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Abstract
Parkinson’s disease (PD) is characterized by progressive loss of nigral dopaminergic neurons, resulting in disabling motor symptoms. Intracerebral transplantation of stem cell-derived dopaminergic progenitors to replace lost endogenous dopaminergic neurons offers a new potentially restorative therapeutic approach for PD. Here we report the 12-month primary safety end point and interim efficacy outcomes from a phase 1/
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.
Code availability
No custom code or algorithm central to the conclusions of this study was developed. Statistical analyses were performed using standard software packages as described in the Methods. Any analysis scripts required to reproduce the reported aggregate analyses are available from the corresponding author on reasonable request, subject to institutional approval.
Reproduced under the paper's license (CC BY), from the paper cited above.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.
Data
No dataset and no data link were found in the paper.
Data availability
The data that support the findings of this study are available within the Article, Extended Data Tables 1–5 and Extended Data Figs. 1 and 2, including Source Data. Additional de-identified participant-level data underlying the results reported in this Article may be made available to qualified researchers on reasonable request, subject to applicable ethical approvals, data protection regulations, participant consent and approval by the study sponsor and relevant institutional data governance bodies. As this is a small first-in-human clinical trial of an advanced therapy medicinal product, individual-level data will not be made publicly available owing to the potential risk of participant re-identification. Requests should include a scientifically sound proposal, a statistical analysis plan and evidence of appropriate ethical and data protection approvals where applicable. Requests will be evaluated by the corresponding author, the study sponsor and relevant institutional representatives. Approved requests will require a data transfer or data use agreement specifying permitted analyses, data security requirements, confidentiality obligations and restrictions on onward sharing. Requests should be directed to Gesine Paul, anticipated response time is within 8–12 weeks of receipt of a complete request. De-identified participant-level data will be available 6 months after publication and for 5 years after publication. The study protocol is available in ref. 37 and as Supplementary Note 1. The clinical trial is registered at ClinicalTrials.gov, NCT05635409 (https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 2, 28 September 2026
- Publisher: n/a → Nature Portfolio
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 21 authors, 2 keywords, 9 MeSH terms, 3 funders, 37 references.
Cite
This paper
Paul, G., Bjartmarz, H., Kirkeby, A., Nelander, J., Smith, R., Kayhanian, S., Evans, A., Harry, B., Cutting, E., Fazal, S., Lao-Kaim, N. P., van Vliet, T., Ullén, S., Grubor, I., Hansson, O., Piccini, P., Lindvall, O., Björklund, A., Widner, H., . . . Barker, R. A. (2026). Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/
BibTeX
@article{paul2026human,
author = {Paul, G and Bjartmarz, H and Kirkeby, A and Nelander, J and Smith, R and Kayhanian, S and Evans, A and Harry, B and Cutting, E and Fazal, S and Lao-Kaim, N P and van Vliet, T and Ullén, S and Grubor, I and Hansson, O and Piccini, P and Lindvall, O and Björklund, A and Widner, H and Parmar, M and Barker, R A},
title = {{Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/
journal = {Nature medicine},
year = {2026},
month = jul,
volume = {32},
number = {9},
pages = {3449--3457},
publisher = {Nature Portfolio},
issn = {1078-8956},
doi = {10.1038/
url = {https://
pmid = {42426223},
pmcid = {PMC13577911}
}
RIS
TY - JOUR
AU - Paul, G
AU - Bjartmarz, H
AU - Kirkeby, A
AU - Nelander, J
AU - Smith, R
AU - Kayhanian, S
AU - Evans, A
AU - Harry, B
AU - Cutting, E
AU - Fazal, S
AU - Lao-Kaim, N P
AU - van Vliet, T
AU - Ullén, S
AU - Grubor, I
AU - Hansson, O
AU - Piccini, P
AU - Lindvall, O
AU - Björklund, A
AU - Widner, H
AU - Parmar, M
AU - Barker, R A
TI - Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/
T2 - Nature medicine
J2 - Nat Med
PY - 2026
DA - 2026/
VL - 32
IS - 9
SP - 3449
EP - 3457
SN - 1078-8956
PB - Nature Portfolio
DO - 10.1038/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1038/
"type": "article-journal",
"title": "Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/
"container-title": "Nature medicine",
"author": [
{
"family": "Paul",
"given": "G"
},
{
"family": "Bjartmarz",
"given": "H"
},
{
"family": "Kirkeby",
"given": "A"
},
{
"family": "Nelander",
"given": "J"
},
{
"family": "Smith",
"given": "R"
},
{
"family": "Kayhanian",
"given": "S"
},
{
"family": "Evans",
"given": "A"
},
{
"family": "Harry",
"given": "B"
},
{
"family": "Cutting",
"given": "E"
},
{
"family": "Fazal",
"given": "S"
},
{
"family": "Lao-Kaim",
"given": "N P"
},
{
"family": "van Vliet",
"given": "T"
},
{
"family": "Ullén",
"given": "S"
},
{
"family": "Grubor",
"given": "I"
},
{
"family": "Hansson",
"given": "O"
},
{
"family": "Piccini",
"given": "P"
},
{
"family": "Lindvall",
"given": "O"
},
{
"family": "Björklund",
"given": "A"
},
{
"family": "Widner",
"given": "H"
},
{
"family": "Parmar",
"given": "M"
},
{
"family": "Barker",
"given": "R A"
}
],
"container-title-short":
"volume": "32",
"issue": "9",
"page": "3449-3457",
"DOI": "10.1038/
"PMID": "42426223",
"PMCID": "PMC13577911",
"ISSN": "1078-8956",
"publisher": "Nature Portfolio",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
9
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1016/j.stemcr.2026.102818
- The immunological profile of RC17 hESC-derived dopaminergic neural progenitor cells in vitro: Implications for the STEM-PD clinical trial.Journal: Stem cell reportsIn common: Parkinson's, 16 references, author S Fazal
- [2] doi:10.1073/pnas.2410331121
- TARGET-seq: Linking single-cell transcriptomics of human dopaminergic neurons with their target specificity.Journal: Proceedings of the National Academy of Sciences of the United States of AmericaIn common: Parkinson's, 5 references, author M Parmar
- [3] doi:10.1016/j.omtm.2023.04.008 [code]
- Deconvolution of spatial sequencing provides accurate characterization of hESC-derived DA transplants <i>in vivo</
i>. Journal: Molecular therapy. Methods & clinical developmentIn common: Parkinson's, 4 references, author M Parmar - [4] doi:10.1126/sciadv.adn3057
- Lineage tracing of stem cell-derived dopamine grafts in a Parkinson's model reveals shared origin of all graft-derived cells.Journal: Science advancesIn common: Parkinson's, 1 reference, 2 authors
- [5] doi:10.1126/sciadv.aed2952 [code]
- Activation of transposable elements is linked to a region- and cell type-specific interferon response in Parkinson's disease.Journal: Science advancesIn common: Parkinson's, 1 reference, 2 authors
- [6] doi:10.1126/sciadv.adq7855
- Three-dimensional cell-cell interactions promote direct reprogramming of patient fibroblasts into functional and transplantable neurons.Journal: Science advancesIn common: 1 reference, 2 authors
- [7] doi:10.1038/s41467-026-71732-1 [code]
- Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer's disease continuum.Journal: Nature communicationsIn common: 2 authors
- [8] doi:10.21203/rs.3.rs-8687892/v1 [code]
- Brain network dynamics determine tau presence while regional vulnerability governs tau load in Alzheimer’s diseaseJournal: Research Square (preprint)In common: 2 authors
- [9] doi:10.1093/brain/awaf279 [code]
- Connectivity as a universal predictor of tau progression in atypical Alzheimer's disease.Journal: Brain : a journal of neurologyIn common: 2 authors
- [10] doi:10.1038/s41467-025-63564-2 [code]
- Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer's Disease.Journal: Nature communicationsIn common: 2 authors
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
